| Literature DB >> 35899130 |
Ling Yu1, Guoping Huang1, Zhihong Lu1, Jingjing Wang1, Weizhong Gu2, Junping Li2, Jianhua Mao1.
Abstract
Patients with epidermolysis bullosa (EB) could develop significant urological complications, such as hydroureteronephrosis, renal amyloidosis and IgA nephropathy (IgAN). Here, we presented a 12-year-old boy carrying pathogenic COL7A1 mutation with diagnosis of dystrophic epidermolysis bullosa (DEB). The patient had concomitant gross hematuria and proteinuria. Pathological examinations and immunostaining of renal biopsy showed glomeruli with mesangial hypercellularity and deposition of IgA, which were indicative of IgAN. Interestingly, serological evaluation showed antineutrophil cytoplasmic antibody (ANCA) directed against myeloperoxidase and proteinase 3. Treatment with glucocorticoid, immunosuppressants, angiotensin-converting enzyme inhibitor and antibiotics efficiently improved hemato-proteinuria, and ANCAs became negative as well. This case of DEB presented a unique collection of clinical manifestations and pathological alterations. IgAN and serum positive ANCA were possibly associated with sustained infection secondary to DEB, and can be managed by empirical treatment for primary IgAN.Entities:
Keywords: IgA nephropathy; anti-MPO; anti-PR3; antineutrophil cytoplasmic antibodies; child; dystrophic epidermolysis bullosa
Year: 2022 PMID: 35899130 PMCID: PMC9309483 DOI: 10.3389/fped.2022.939069
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.569
FIGURE 1Clinical image of the dystrophic epidermolysis bullosa patient and histology from renal biopsy. (A) Skin scarring on feet, pseudosyndactyly and nail dystrophy. (B) H&E staining. (C) Electron micrography image. (D) IgA immunofluorescence staining. (E) C3 immunofluorescence staining.
Laboratory data on first admission.
| Results | Reference range | |
|
| ||
| Occult blood | 3 + | Negative |
| RBCs (per HPF) | 322 | 0–3 |
| Protein/creatinine ratio (mg/mg) | 3.49 | <0.20 |
| 24-h urinary protein (mg) | 1273.3 | <150 |
|
| ||
| WBC (thousand/mm3) | 5.69 | 4.00–12.00 |
| Hemoglobin (g/L) | 75 | 110–155 |
| Platelet (thousand/mm3) | 328 | 100–400 |
| hsCRP (mg/L) | 13.25 | 0.00–8.00 |
| SAA (mg/L) | 32.2 | 0.0–10.0 |
| Albumin (g/L) | 28.1 | 32.0–52.0 |
| Cholesterol (mmol/L) | 4.01 | 3.00–5.70 |
| Urea nitrogen (mmol/L) | 2.10 | 2.80–7.60 |
| Creatinine (μmol/L) | 25 | 21–65 |
| ESR (mm/h) | >110 | 0–20 |
| ANA | 1:100 | <1:100 |
| Anti-dsDNA (IU/mL) | <1:100 | <1:100 |
| P-ANCA | 1:100 | <1:20 |
| C-ANCA | 1:100 | <1:20 |
| Anti-MPO (RU/mL) | 132.20 | 0–20 |
| Anti-PR3 (RU/mL) | 71.11 | 0–20 |
| Immunoglobulin G (g/L) | 23.8 | 6.36–13.24 |
| Immunoglobulin A (g/L) | 9.10 | 0.49–2.29 |
| Immunoglobulin M (g/L) | 1.99 | 0.42–1.46 |
| Immunoglobulin E (IU/mL) | 315.0 | 0.0–100.0 |
| C3 (g/L) | 1.602 | 0.900–1.800 |
| C4 (g/L) | 0.347 | 0.100–0.400 |
| Viral hepatitis panel | Negative | Negative |
| HIV, syphilis and TB screening | Negative | Negative |
RBCs, red blood cells; WBC, white blood cells; hsCRP, hypersensitive C-reactive protein; SAA, serum amyloid A; ESR, erythrocyte sedimentation rate; ANA, anti-nuclear antibody; Anti-dsDNA, anti-double-stranded DNA antibody; P-ANCA, perinuclear antineutrophil cytoplasmic antibody; C-ANCA, cytoplasmic antineutrophil cytoplasmic antibody; Anti-MPO, antibody against myeloperoxidase; Anti-PR3, antibody against proteinase 3; C3, complement 3; C4, complement 4; TB, tuberculosis.
FIGURE 2Twenty four hour urinary protein over the treatment course. The arrow indicated the time points when skin lesions worsened.